

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
11 March 2004 (11.03.2004)

PCT

(10) International Publication Number  
**WO 2004/020411 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 211/26**,  
A61K 31/451, A61P 25/00, 9/00

[US/US]; AstraZeneca Wilmington, P.O. Box 15437,  
Wilmington, DE 19850-5437 (US).

(21) International Application Number:  
PCT/SE2003/001329

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; As-  
traZeneca AB, S-151 85 Södertälje (SE).

(22) International Filing Date: 26 August 2003 (26.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0202567-4 29 August 2002 (29.08.2002) SE  
0202986-6 9 October 2002 (09.10.2002) SE

(71) Applicant (for all designated States except US): **AS-  
TRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BERNSTEIN, Pe-  
ter** [US/US]; AstraZeneca Wilmington, P.O. Box 15437,  
Wilmington, DE 19850-5437 (US). **DANTZMAN, Cathy**  
[US/US]; AstraZeneca Wilmington, P.O. Box 15437,  
Wilmington, DE 19850-5437 (US). **DEDINAS, Robert**  
[US/US]; AstraZeneca Wilmington, P.O. Box 15437,  
Wilmington, DE 19850-5437 (US). **SHEN, Lihong**  
[US/US]; AstraZeneca Wilmington, P.O. Box 15437,  
Wilmington, DE 19850-5437 (US). **WARWICK, Paul**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: NAPHTHAMIDE DERIVATIVES AND THEIR USE



(57) Abstract: Compounds having the following structure wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, m and n are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically-acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same.



Applicant: **AstraZeneca Aktiebolag**  
**S-151 85 Södertälje**  
**Sweden**

Title: **NAPHTHAMIDE DERIVATIVES AND THEIR USE**

Reference: **100819**

Inventors: **Peter R. Bernstein**  
**Lihong Shen**  
**Robert F. Dedinas**  
**Paul J. Warwick**  
**Cathy L. Dantzman**

- 1 -

## NAPHTHAMIDE DERIVATIVES AND THEIR USE

### FIELD OF THE INVENTION

This invention relates to the treatment of diseases in which serotonin and Substance P or Neurokinin A are implicated, for example, in the treatment of disorders or conditions such as hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's disease, endocrine disorders vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder, chronic paroxysmal hemicrania and headache.

### BACKGROUND

The mammalian neurokinins are peptide neurotransmitters found in the peripheral and central nervous systems. The three principal neurokinins are Substance P (SP), Neurokinin A (NKA) and Neurokinin B (NKB). N-terminally extended forms of at least NKA are known. Three receptor types are known for the principal neurokinins. Based upon their relative selectivities for the neurokinins SP, NKA and NKB, the receptors are classified as neurokinin 1 (NK<sub>1</sub>), neurokinin 2 (NK<sub>2</sub>) and neurokinin 3 (NK<sub>3</sub>) receptors, respectively. In the periphery, SP and NKA are localized in C-afferent sensory neurons, which neurons are characterized by non-myelinated nerve endings known as C-fibers, and are released by selective depolarization of these neurons, or selective stimulation of the C-fibers. C-Fibers are located in the airway epithelium, and the tachykinins are known to cause profound effects which clearly parallel many of the symptoms observed in asthmatics. The effects of release or introduction of tachykinins in mammalian airways include bronchoconstriction, increased microvascular permeability, vasodilation, increased mucus secretion and activation of mast cells. Neurokinin antagonists that interact with NK<sub>1</sub>, NK<sub>2</sub> and NK<sub>3</sub> receptors, having different chemical structures have been described.

NK<sub>1</sub> activity is also implicated in depression and anxiety, mice with genetically altered NK<sub>1</sub> receptors have decreased anxiety related behavior (Santarelli, L., *et al.*, Proc. Nat. Acad. Sci.

- 2 -

(2001), 98, 1912) and NK<sub>1</sub> antagonists have been reported to be effective in an animal model of depression (Papp, M., *et al.*, Behav. Brain Res. (2000), 115, 19).


Serotonin Selective Reuptake Inhibitors (SSRIs) are widely used for the treatment of major depressive disorder (MDD) and are considered well-tolerated and easily administered.

5 SSRIs, however, have a delayed onset of action, are associated with undesirable side effects, such sexual dysfunction, and are ineffective in perhaps 30% of patients (M. J. Gitlin, MJ, J. Clin. Psych., 55, 406-413, 1994).

Compounds with dual action as NK<sub>1</sub> antagonists and serotonin reuptake inhibitors may, therefore provide a new class of antidepressants. Indeed, compounds combining NK<sub>1</sub> antagonism  
10 and serotonin reuptake inhibition have been described (Ryckmans, T., *et al.*, Bioorg. Med. Chem. Lett. (2002), 12, 261).

#### SUMMARY OF THE INVENTION

We have discovered naphthamide derivatives having both neurokinin 1 (NK<sub>1</sub>) antagonist activity and serotonin reuptake inhibitory (SRI) activity. Naphthamide derivatives of the  
15 invention are compounds in accord with structural diagram I:



wherein:

R<sup>1</sup> independently at each occurrence is CN, CF<sub>3</sub>, OCF<sub>3</sub>, OCHF<sub>2</sub>, halogen, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, R<sup>a</sup>, R<sup>b</sup>, SR<sup>a</sup>, NR<sup>a</sup>R<sup>b</sup>, CH<sub>2</sub>NR<sup>a</sup>R<sup>b</sup>, OR<sup>a</sup> or CH<sub>2</sub>OR<sup>a</sup>, where R<sup>a</sup> and R<sup>b</sup> are independently at  
20 each occurrence hydrogen, C<sub>1-6</sub>alkyl, C(O)R<sup>c</sup>, C(O)NHR<sup>c</sup> or CO<sub>2</sub>R<sup>c</sup>, where R<sup>c</sup> at each occurrence is C<sub>1-6</sub>alkyl; or, R<sup>a</sup> and R<sup>b</sup> together are (CH<sub>2</sub>)<sub>j</sub>G(CH<sub>2</sub>)<sub>k</sub> or G(CH<sub>2</sub>)<sub>j</sub>G, where G is oxygen or sulfur, j is 1, 2, 3 or 4, and k is 0, 1 or 2;

m is 1, 2 or 3 where at least one R<sup>1</sup> moiety is other than hydrogen;

R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkyl substituted with C<sub>1-4</sub>alkoxy;

25 R<sup>4</sup> independently at each occurrence is hydrogen, CN, CF<sub>3</sub>, OCF<sub>3</sub>, OCHF<sub>2</sub>, halogen, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, SR<sup>a</sup>, NR<sup>a</sup>R<sup>b</sup>, CH<sub>2</sub>NR<sup>a</sup>R<sup>b</sup>, OR<sup>a</sup> or CH<sub>2</sub>OR<sup>a</sup>, where R<sup>a</sup> and R<sup>b</sup> are independently at each occurrence hydrogen, C<sub>1-6</sub>alkyl, C(O)R<sup>c</sup>, C(O)NHR<sup>c</sup> or CO<sub>2</sub>R<sup>c</sup> where R<sup>c</sup> at

- 3 -


each occurrence is  $C_{1-6}$ alkyl; or,  $R^a$  and  $R^b$  together are  $(CH_2)_jG(CH_2)_k$  or  $G(CH_2)_jG$  where G is oxygen or sulfur, j is 1, 2, 3 or 4, k is 0, 1 or 2, and

n is 0, 1, 2 or 3.

The invention also encompasses in vivo-hydrolysable precursors and pharmaceutically-acceptable salts of the naphthamide derivatives, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them, uses of them as medicaments, uses of them in the manufacture of medicaments and uses of them for diagnostic and analytic purposes.

## 10 DETAILED DESCRIPTION OF THE INVENTION

Compounds of the present invention are those in accord with structural diagram I:



wherein:

$R^1$  at each occurrence is independently selected from CN,  $CF_3$ ,  $OCF_3$ ,  $OCHF_2$ , halogen,  $C_{2-4}$ alkenyl,  $C_{2-4}$ alkynyl,  $R^a$ ,  $R^b$ ,  $SR^a$ ,  $NR^aR^b$ ,  $CH_2NR^aR^b$ ,  $OR^a$  or  $CH_2OR^a$ , where  $R^a$  and  $R^b$  are independently at each occurrence hydrogen,  $C_{1-6}$ alkyl,  $C(O)R^c$ ,  $C(O)NHR^c$  or  $CO_2R^c$ , where  $R^c$  at each occurrence is  $C_{1-6}$ alkyl; or,  $R^a$  and  $R^b$  together are  $(CH_2)_jG(CH_2)_k$  or  $G(CH_2)_jG$ , where G is oxygen or sulfur, j is 1, 2, 3 or 4, and k is 0, 1 or 2;

m is 1, 2 or 3 where at least one  $R^1$  moiety is other than hydrogen;

$R^2$  and  $R^3$  are independently hydrogen,  $C_{1-6}$ alkyl or  $C_{1-6}$ alkyl substituted with  $C_{1-4}$ alkoxy;

$R^4$  at each occurrence is independently selected from hydrogen, CN,  $CF_3$ ,  $OCF_3$ ,  $OCHF_2$ , halogen,  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{2-4}$ alkynyl,  $SR^a$ ,  $NR^aR^b$ ,  $CH_2NR^aR^b$ ,  $OR^a$  or  $CH_2OR^a$ , where  $R^a$  and  $R^b$  are independently at each occurrence hydrogen,  $C_{1-6}$ alkyl,  $C(O)R^c$ ,  $C(O)NHR^c$  or  $CO_2R^c$  where  $R^c$  at each occurrence is  $C_{1-6}$ alkyl; or,  $R^a$  and  $R^b$  together are  $(CH_2)_jG(CH_2)_k$  or  $G(CH_2)_jG$ , and

n is 0, 1, 2 or 3;

in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

- 4 -

Other particular compound of the invention are those wherein:

$R^1$  independently at each occurrence is CN,  $C_{1-6}$ alkyl or  $OR^e$  and m is 1, 2 or 3;

$R^2$  and  $R^3$  are independently hydrogen or  $C_{1-6}$ alkyl, and

$R^4$  independently at each occurrence is halogen where n is 1 or 2;

5 in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

More particular compound of the invention are those wherein:

$R^1$  independently at each occurrence is CN, ethyl or methoxy and m is 1, 2 or 3;


$R^2$  and  $R^3$  are independently hydrogen or methyl, and

$R^4$  independently at each occurrence is halogen where n is 1 or 2;

10 in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

Particular compounds of the invention are those wherein Ar,  $R^1$ ,  $R^2$  and  $R^3$  are moieties identified in Table 2 and Table 3, herein.

Particular compounds of the invention are those according to structural diagram II



II

15

wherein Ar is selected from phenyl, 3,4-dichlorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 4-difluoromethoxyphenyl or 4-trifluoromethoxyphenyl;  $R^1$  is selected from H, methyl, ethyl or methoxy where m is 1 or 2 and  $R^2$  and  $R^3$  are independently is selected from H or methyl, and

20 in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

Most particular compounds of the invention are those described herein in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

Pharmaceutically-acceptable salts of compounds in accord with structural diagram I include those made with inorganic or organic acids which afford a physiologically-acceptable anion, such as with, for example, hydrochloric, hydrobromic, sulfuric, phosphoric, 25 methanesulfonic, sulfamic, para-toluenesulfonic, acetic, citric, lactic, tartaric, malonic, fumaric, ethanesulfonic, benzenesulfonic, cyclohexylsulfamic, salicylic and quinic acids.

- 5 -

In order to use a compound in accord with structural diagram I or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof for the therapeutic treatment or prophylactic treatment of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

5 Therefore, another aspect the present invention is a pharmaceutical composition comprising a compound in accord with structural diagram I, an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable carrier.

Pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, topical, parenteral, buccal,  
10 nasal, vaginal or rectal administration or by inhalation or insufflation. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aq. or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aq. or oily solutions  
15 or suspensions or sterile emulsions.

In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to herein.

20 The pharmaceutical compositions of this invention will normally be administered to humans so that, for example, a daily dose of 0.01 to 25 mg/kg body weight (and preferably of 0.1 to 5 mg/kg body weight) is received. This daily dose may be given in divided doses as necessary, the precise amount of the compound received and the route of administration depending on the weight, age and sex of the patient being treated and on the particular disease condition being  
25 treated according to principles known in the art.

Typically unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention. For example a tablet or capsule for oral administration may conveniently contain up to 250 mg (and typically 5 to 100 mg) of a compound in accord with structural diagram I or a pharmaceutically-acceptable salt thereof. In another example, for administration by inhalation, a  
30 compound in accord with structural diagram I or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof may be administered in a daily dosage range of 5 to 100

- 6 -

mg, in a single dose or divided into two to four daily doses. In a further example, for administration by intravenous or intramuscular injection or infusion, a sterile solution or suspension containing up to 10% w/w (and typically 5% w/w) of a compound in accord with structural diagram I or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof may be used.

Yet a further aspect of the present invention is a method of treating a disease condition wherein antagonism of NK<sub>1</sub> receptors in combination with SRI activity is beneficial which method comprises administering to a warm-blooded animal an effective amount of a compound in accord with structural diagram I or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof. The present invention also provides the use of a compound in accord with structural diagram I or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof in the preparation of a medicament for use in a disease condition wherein antagonism of the NK<sub>1</sub> receptors and SRI activity is beneficial.

The present invention also relates to a method for treating a disorder or condition selected from hypertension, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, post partum depression, generalized anxiety disorder, agoraphobia, social phobia, simple phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, anorexia nervosa, bulimia nervosa, obesity, addictions to alcohol, cocaine, heroin, phenobarbital, nicotine or benzodiazepines; cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, dementia, amnesic disorders, age-related cognitive decline, dementia in Parkinson's disease, neuroleptic-induced parkinsonism, tardive dyskinesias, hyperprolactinaemia, vasospasm, cerebral vasculature vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder, chronic paroxysmal hemicrania and headache associated with vascular disorders in a mammal, comprising administering an effective amount of a compound in accord with structural diagram I or a pharmaceutically-acceptable salt thereof effective in treating such disorder or condition and a pharmaceutically-acceptable carrier.



- 7 -

The present invention also relates to a pharmaceutical composition for treating a disorder or condition selected from hypertension, depression (e.g., depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, 5 single episode depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines), cluster 10 headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnesic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract 15 disorders (involving changes in motility and secretion), negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder (ADHD), chronic paroxysmal hemicrania and headache (associated with vascular disorders) in a mammal, preferably a human, comprising an effective amount of a compound in accord with structural 20 diagram I or a pharmaceutically-acceptable salt thereof effective in treating such disorder or condition and a pharmaceutically-acceptable carrier.

Compounds in accord with structural diagram I and their in vivo-hydrolysable precursors or a pharmaceutically-acceptable salts may be made by processes as described and exemplified herein and by processes similar thereto and by processes known in the chemical art. If not 25 commercially available, starting materials for these processes may be made by procedures which are selected from the chemical art using techniques which are similar or analogous to the synthesis of known compounds.

Pharmaceutically-acceptable salts may be prepared from the corresponding acid in a conventional manner. Non-pharmaceutically-acceptable salts may be useful as intermediates and 30 as such are another aspect of the present invention.

- 8 -

It is well known in the art how to prepare optically-active forms (for example, by resolution of the racemic form or by synthesis from optically-active starting materials) and all optically active forms, enantiomers are compounds of this invention.

The following biological test methods, data and Examples serve to illustrate and further  
5 describe the invention.

The utility of a compound of the invention or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof (hereinafter, collectively referred to as a "Compound") may be demonstrated by standard tests and clinical studies, including those disclosed in the publications described below.

10 Biological Assays:

SERT Binding Assay:

Frozen membrane preparations of a stably transfected HEK293 cell line expressing human 5-HTT receptors were purchased from Receptor Biology (PerkinElmer). Frozen aliquots were rapidly thawed, homogenized, and diluted in assay buffer (AB) containing 50 mM TRIS-  
15 HCL, 120 mM NaCl, 5 mM KCl and adjusted to pH 7.4 with NaOH. Final protein concentration was 40 µg/ml. Test compounds were evaluated in competition assays utilizing [<sup>3</sup>H]-Imipramine Hydrochloride purchased from NEN (PerkinElmer) as the radioligand. The stock radioligand was diluted with AB for a final concentration of approximately 2 nM. K<sub>d</sub> for [<sup>3</sup>H]-Imipramine Hydrochloride was determined to be 2.7 nM. The competition assays were performed on 96-well  
20 assay plates – two drugs per plate. Ten serial dilutions (normally 1 µM to 38 pM final concentration) from stock 10 mM solutions of compounds prepared in DMSO. All serial dilutions were made using 20% DMSO. DMSO content in assay is less than 1%. Incubation mixtures were prepared in quadruplicate in 96-well plates (Costar). Final assay volumes per well were 10 µl compound/nonspecific/control (1% DMSO), 20 µl membranes, 20 µl [<sup>3</sup>H]-Imipramine  
25 Hydrochloride, and 150 µl AB. Specific binding was defined by using 10 µM Imipramine. The binding reaction was initiated by adding membranes immediately after adding the radioligand to wells containing buffer plus either test compound, nonspecific, or control. The assay plates were placed on a plate shaker and shaken for thirty minutes while the reactions reached equilibrium. The plates were then filtered through Beckman GF/B filters, presoaked in 6% PEI, using a  
30 Packard Filtermate 196. Filters were washed 5x with 0.2 ml ice-cold wash buffer (5 mM Tris HCl, pH 7.4.) After filters dried, 35 µl of Microscint20 (Packard) was added to each well. The

- 9 -

plates were then counted on a Packard TopCount to determine CPM's per well. Ki values were determined for each test compound utilizing the graphic and analytical software package, GraphPad Prism.

NK<sub>1</sub> FLIPR Assay using Fluo-4 Dye:

- 5 FLIPR assays are performed with a device marketed by Molecular Devices, Inc., designed to precisely measure cellular fluorescence in a high throughput whole-cell assay. (Schroeder et al., J. Biomolecular Screening, 1(2), p 75-80, 1996).

Compounds were evaluated for potency in blocking the response of U373 cells to the NK<sub>1</sub> receptor agonist Acetyl-[Arg<sup>6</sup>, Sar<sup>9</sup>, Met(O<sub>2</sub>)<sup>11</sup>]-Substance P (ASMSP) using a FLIPR instrument.

- 10 U373 cells were loaded with Fluo-4 dye (Molecular Probes) for 45 min at 37 °C and exposed to graded concentrations of compounds for 15 min at room temperature before being challenged with 10 nM – 12 nM ASMSP (an approximately EC<sub>80</sub> concentration). Responses were measured as the peak relative fluorescence after agonist addition. pIC<sub>50</sub>s were calculated from eleven-point concentration-response curves for each compound.

15 Reagents:

Cell culture medium:

- |   |                   |
|---|-------------------|
| Eagle's MEM with Earle's salts and l-glutamine (500 mL) | Cellgro 10-010-CV |
| Non-essential amino acids, 100 x (5 mL)                 | Cellgro 25-025-CI |
| Sodium pyruvate, 100 mM (5 mL)                          | Cellgro 25-000-CI |
| 20 L-Glutamine, 200 mM (5 mL)                           | Cellgro 25-005-CI |
| FBS (50 mL)   | Cellgro 35-010-CV |

Cell harvesting reagents:

- |  |                   |
|--|-------------------|
| DPBS, 1x without Ca <sup>++</sup> & Mg <sup>++</sup> | Cellgro 21-031-CV |
| 1x Trypsin –EDTA (0.5% Trypsin, 0.53% EDTA-4Na)      | Cellgro 25-052-CI |

25 Cell plating medium:

- |                                   |                      |
|-----------------------------------|----------------------|
| UltraCULTURE                      | BioWhittaker 12-725F |
| L-Glutamine, 200 mM (5 mL/500 mL) | Cellgro 25-005-CI    |

Working buffer:

- |  |                   |
|--|-------------------|
| 10x Hank's balanced salt solution (100 mL/L)         | Gibco 14065-056   |
| 30 HEPES buffer 1 M (15 mL/L, [final] 15 mM)         | Cellgro 25-060-CI |
| Probenecid (0.71g dissolved in 6 mL 1 M NaOH for 1L, |                   |

- 10 -

[final] 2.5 mM)

Sigma P-8761

DDH<sub>2</sub>O to 1 L, adjust pH to 7.4 with NaOH

Dye solution:

Fluo-4, AM dye, Molecular Probes F-14201. 50 µg lyophilized dye is dissolved in 23 µL DMSO  
5 plus 23 µL Pluronic F-127 (Molecular Probes P-3000). The 46 µL of solubilized fluo-4 dye is  
then added to 10 mL of working buffer solution to provide a working dye concentration of 5 µM.  
Each 10 mL of diluted dye is sufficient for a 384-well-plate of cells at 25 µL per well.

Agonist:

Acetyl-[Arg<sup>6</sup>, Sar<sup>9</sup>, Met(O<sub>2</sub>)<sup>11</sup>]-Substance P (ASMSP)

10 Stock solution of 3.33x10<sup>-2</sup> M. Dissolve 100 mg in 3.05 mL DMSO and store in aliquots at 4 °C

Miscellaneous:

DMSO (to dissolve compounds and for tip wash)

Cell culture and plating procedures:

U373 cells were grown in cell culture medium described above (30 mL per T-150 flask)  
15 and harvested when confluent as follows. Medium was removed by aspiration and cells were  
washed with 12 mL DPBS, 1x without Ca<sup>++</sup> and Mg<sup>++</sup>. The DPBS was aspirated and replaced  
with 3 mL trypsin -EDTA. The cells plus trypsin/EDTA were incubated about 2 minutes at  
room temperature, until the cells detached from the flask. The harvesting reaction was quenched  
by addition of 9 mL culture medium and cells were resuspended by trituration.  
20 Cells were passaged at a transfer density of 1:4 every four days. For experiments, cells were  
counted, pelleted by centrifugation at 400 x g for 5 min and resuspended in cell plating medium  
at a density of 480,000 cells/mL. 25 µL of this cell suspension was added to each well of a  
black-walled 384-well plate (Falcon Microtest, 35 3962) using a Labsystems Multidrop 384 to  
give 12,000 cells per well. Plates were incubated at 37 °C overnight (minimum 15 h, maximum  
25 23 h) before use.

Compound and agonist preparation:

Compounds were dissolved in DMSO at a concentration of 10 mM and 120 µL of these  
solutions were transferred to the first well (column 1) of each row of a 96-well, round-bottomed,  
polypropylene storage plate (Costar 3365). Compounds on two such plates were then serially  
30 diluted simultaneously in DMSO using a Biomek 2000. 4 µL of each dilution was transferred to  
a deep well plate (Beckman Coulter 267006) which had been prepared previously to contain 400

- 11 -

μL of freshly made working buffer in each well. Concentrations resulting from this procedure are shown in Table 1. The final compound concentrations in the assay span 11 points, between 10 μM and 0.1 nM, in half-log increments.

Table 1. Concentrations of compound and DMSO in various wells of a 96-well plate after serial dilution using Biomek 2000

Column number	Compound (Molarity)	DMSO (%)
1	1e-4	1
2	3e-5	1
3	1e-5	1
4	3e-6	1
5	1e-6	1
6	3e-7	1
7	1e-7	1
8	3e-8	1
9	1e-8	1
10	3e-9	1
11	1e-9	1
12	none	1

The contents of the deep wells were mixed, and 45 μL of each dilution were transferred, in duplicate, to a 384-well polypropylene compound loading plate (Fisher 12-565-507) so that the 384-well plate contained duplicates of each of the compounds from both 96-well plates in the concentrations shown in table 1. Columns 23 & 24 of the plate contain no compound and serve as controls. Wells A – N in columns 23 and 24 were loaded with agonist only and therefore represent the maximal response. Wells O – P in columns 23 and 24 were loaded with only buffer, no agonist, and therefore represent the minimum response.

An ASMSP agonist loading plate was made by taking stock concentration of ASMSP and diluting in working buffer to give a concentration of  $3.3 \times 10^{-8}$  M. 45 μL of this solution were transferred to all wells of a 384-well polypropylene agonist loading plate (Fisher 12-565-507)

- 12 -

except wells O23, O24, P23 & P24 which contained buffer alone and served as unstimulated controls.

Dye Loading cells and adding compound:

For each 384-well assay plate of cells, 10 mL of diluted Fluo-4 dye was prepared as stated  
5 above in the methods/reagents section. First, each 384-well cell plate was washed once with  
working buffer on a CCS Packard plate washer. Any remaining post-wash buffer in the wells  
was removed by hand and 25  $\mu$ L per well of Fluo-4 dye was added using a Labsystems Multidrop  
384. The cell plate was returned to a 37 °C incubator for 45 min to allow the dye to permeate the  
cells. After 45 min of dye loading, the cell plates were washed twice with working buffer,  
10 leaving a 30  $\mu$ L volume of buffer in each well. 5  $\mu$ L of compound dilutions were transferred  
from the compound plate to the cell plate using a PlateMate. Assay plates were incubated in the  
presence of compound for 15 min at room temperature in the dark, and then loaded onto FLIPR.

Recording responses in FLIPR:

After the 15 min compound pre-incubation, the plates were loaded onto the FLIPR  
15 instrument, 15  $\mu$ L of ASMSP agonist was added and the cellular response to the agonist was  
recorded for 90 seconds. The response is measured as the peak relative fluorescence after agonist  
addition.

Data analysis:

Results contained in the .stat files generated by FLIPR were pasted into an Excel analysis  
20 template and, after outliers were excluded, IC<sub>50</sub> values were calculated within the template using  
XLfit. Individual IC<sub>50</sub> values were reported, along with pIC<sub>50</sub>. When the two IC<sub>50</sub>'s obtained for  
a compound differed by more than 3-fold that compound was assayed one or two more times to  
re-determine the value.

Compounds of the present invention exhibit a K<sub>i</sub> in the range of 1 to 100 nM in the SERT  
25 assay and have an IC<sub>50</sub> in the range 1 to 100 nM in FLIPR assay

The invention is illustrated by, but not limited to, the following examples in which  
descriptions, where applicable and unless otherwise stated, the following terms, abbreviations  
and conditions are used:

Abbreviations used herein are as follows: aq., aqueous; atm, atmospheric pressure; BOC,  
30 1,1-dimethylethoxycarbonyl; DCM, dichloromethane; DMF, N,N-dimethylformamide; DMSO,  
dimethyl sulfoxide; EtOH, ethanol; Et<sub>2</sub>O, diethyl ether; EtOAc, ethyl acetate; h, hour(s); HPLC,

- 13 -

high pressure liquid chromatography; HOBT, 1-hydroxybenzotriazole; MeOH, methanol; min, minutes; MS, mass spectrum; NMR, nuclear magnetic resonance; psi, pounds per square inch; RT, room temperature; sat., saturated; TEA, triethylamine; TFA, trifluoroacetic acid; THF, tetrahydrofuran.

- 5           Temperatures are given in degrees Celsius (°C); unless otherwise stated, operations were carried out at room or ambient temperature (18-25 °C).

Organic solutions were dried over anhydrous sodium or magnesium sulfate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (4.5-30 mm Hg) with a bath temperature of up to 60 °C.

- 10           Chromatography means flash column chromatography on silica gel unless otherwise noted; solvent mixture compositions are given as volume percentages or volume ratios.

When given, NMR data is in the form of delta values for major diagnostic protons (given in parts per million (ppm) relative to tetramethylsilane as an internal standard) determined at 300 MHz.

- 15           Melting points are uncorrected.

Mass spectra (MS) were obtained using an automated system with atmospheric pressure chemical ionization (APCI) unless otherwise indicated. Masses corresponding to the major isotopic component, or the lowest mass for compounds with multiple masses with nearly equivalent abundance (isotope splitting), are reported.

- 20           "Halogen" or "halo," as used herein means, fluoro, chloro, bromo and iodo.


- Where noted that a final compound was converted to the citrate salt, the free base was dissolved in methanol, DCM, or acetonitrile, combined with citric acid (1.0 equivalents) in methanol, concentrated under reduced pressure and dried under vacuum (25-60 °C). When indicated that the salt was isolated by filtration from Et<sub>2</sub>O, the citrate salt of the compound was stirred in Et<sub>2</sub>O for 4-18 h, recovered by filtration, washed with Et<sub>2</sub>O, and dried under vacuum (25-60 °C).
- 25

#### EXAMPLES

Example 1: 1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine.

- 30           The title compound of the following structure

- 14 -



was prepared as a citrate hemihydrate, as follows. A solution containing 3-cyano-1-naphthoyl chloride (as described in US patent 6,365,602) (141.2 mg, 0.655 mmol) and dry DCM (2 mL) was added in portions (0.25 mL) to a stirred solution containing 1-N-methyl-4-(3,4-dichlorophenyl)-4-(N-methylaminomethyl)piperidine (195.5 mg, 0.681 mmol), TEA (0.13 mL), and dry DCM (5 mL) at RT. After 72h, the mixture was partitioned between DCM and 1M aq. HOAc, the organic layer was removed, and the aq. layer extracted with additional DCM (4X). The organic extracts were combined, washed (sat. aq. NaHCO<sub>3</sub>), dried, filtered, and concentrated. The residue was purified by chromatography (2-10% MeOH-DCM w/0.5% aq. NH<sub>3</sub>) and crystallization (DCM-hexane), converted to the citrate salt and isolated by filtration from Et<sub>2</sub>O to give the title compound as a white powder. MS m/z 466 (M+H). Analysis for C<sub>26</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>3</sub>O · 1.0 C<sub>6</sub>H<sub>8</sub>O<sub>7</sub> · 0.5 H<sub>2</sub>O: Calculated: C, 57.58; H, 5.13; N, 6.29. Found: C, 57.42; H, 5.05; N, 6.24.

The requisite 1-N-methyl-4-(3,4-dichlorophenyl)-4-(N-methylaminomethyl)piperidine was prepared as follows:

a) 1-N-Methyl-4-(3,4-dichlorophenyl)-4-(N-methylaminomethyl)piperidine.

A solution containing 1-N-methyl-4-(3,4-dichlorophenyl)-4-(ethoxycarbonylaminomethyl)piperidine (2.14 g, 6.2 mmol) and dry THF (20 mL) was added to a LiAlH<sub>4</sub> and THF (40 mL) mixture at room temperature. The mixture was boiled under reflux for 1h, cooled to RT, and carefully treated with Na<sub>2</sub>SO<sub>4</sub> · 10 H<sub>2</sub>O (in portions) until no further gas evolution was noted. The mixture was stirred at RT for 18h, filtered, and the solids washed with additional THF and toluene. The filtrates and washings were combined and concentrated to give the title compound as a light-yellow solid. The material was used without further purification. MS m/z 287 (M+H).

b) 1-Methyl-4-(3,4-dichlorophenyl)-4-(ethoxycarbonylaminomethyl)piperidine

A solution containing 1-N-methyl-4-aminomethyl-4-(3,4-dichlorophenyl)piperidine (2.13 g, 7.80 mmol), TEA (1.36 mL), and dry DCM (15 mL) was cooled (ice bath), and a solution containing ethyl chloroformate (0.93 mL) and DCM (5 mL) was added dropwise over 20 min. After 40 min, cooling was removed and the solution was stirred at RT for an additional 3h. The



- 15 -

reaction was diluted with additional DCM, washed with sat. aq.  $\text{NaHCO}_3$  and brine, dried, filtered and concentrated. The residue was purified by chromatography (5-10% MeOH/DCM) to give the title compound as a viscous oil. MS m/z 345 (M+H).

c) 1-N-Methyl-4-aminomethyl-4-(3,4-dichlorophenyl)piperidine


5 A mixture containing 1-N-methyl-4-(3,4-dichlorophenyl)-4-cyanopiperidine (2.1 g, 7.8 mmol), Raney Ni catalyst (1g of 50% aq. slurry), EtOH (50 mL), and ammonium hydroxide (25 mL) was placed under a hydrogen atmosphere (50 psi) and agitated (Parr apparatus) for 18 h. The mixture was filtered through diatomaceous earth and concentrated to give the title compound as a viscous oil that was used without further purification. MS m/z 273 (M+H).

10 d) 1-N-Methyl-4-(3,4-dichlorophenyl)-4-cyanopiperidine.

According to procedures given in J. Het Chem., 20, 771 (1983); *ibid.*, 23, 73 (1986), a mixture containing 3,4-dichlorophenylacetonitrile (4.9 g, 26.44 mmol), N-methyl-bis-(2-chloroethyl)amine hydrochloride (5.1 g, 26.49 mmol), hexadecyltributylphosphonium bromide (0.72g, 1.43 mmol), and 50% aq. sodium hydroxide (30 mL) was heated at 100 °C for 1 hour,  
 15 allowed to cool, treated with water (100 mL), and extracted with  $\text{Et}_2\text{O}$  (3X). The ether extracts were combined, washed with water (1X), and extracted with 1N aq. HCl (5X). The acidic extracts were washed with  $\text{Et}_2\text{O}$ , neutralized with solid sodium carbonate, and extracted with  $\text{Et}_2\text{O}$  (2X). The ether extracts were dried, filtered and concentrated. The residual oil was purified by chromatography (0.5-2% MeOH/DCM) to give the title compound as a yellow oil. MS m/z  
 20 269 (M+H).

Example 2: 1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine.

The title compound of the following structure



25


was prepared as a citrate hydrate, as follows. A solution containing 3-cyano-2-methoxy-1-naphthoyl chloride (described in international publication WO 00/20389) (151.9 mg, 0.618 mmol) and dry DCM (2 mL) was added in portions (0.25 mL) to a stirred solution containing 1-

- 16 -

N-methyl-4-(3,4-dichlorophenyl)-4-(N-methylaminomethyl)piperidine (183.3 mg, 0.638 mmol), TEA (0.12 mL), and dry DCM (5 mL) at RT. After 72h, the mixture was partitioned between DCM and 1M aq. HOAc, the organic layer was removed, and the aq. layer extracted with additional DCM (4X). The organic extracts were combined, washed (sat. aq. NaHCO<sub>3</sub>), dried, filtered, and concentrated. The residue was purified by chromatography (2-10% MeOH-DCM w/0.5% aq. NH<sub>3</sub>), converted to the citrate salt and isolated by filtration from Et<sub>2</sub>O to give the title compound (white powder) as a mixture of (E) and (Z) amides. MS m/z 496 (M+H). Analysis for C<sub>27</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub> · 1.0 C<sub>6</sub>H<sub>8</sub>O<sub>7</sub> · 1.0 H<sub>2</sub>O: Calculated: C, 56.10; H, 5.28; N, 5.95. Found: C, 56.44; H, 5.10; N, 5.98.

Example 3: 4-(3,4-Dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure



was prepared as a citrate, as follows. A solution containing 1-N-BOC-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine (329 mg, 0.579 mmol) and DCM (5 mL) was stirred at room temperature and TFA (5 mL) was slowly added. After 18 h, the solution was concentrated, and the residue partitioned between DCM and sat. aq. NaHCO<sub>3</sub>. The organic layer was removed and the basic aq. layer was extracted with additional DCM (2X). The organic extracts were combined, dried, filtered, and concentrated. The residue was purified by chromatography (0-5% MeOH/DCM w/0.5% aq. NH<sub>3</sub>) and converted to the citrate salt to give the title compound as a white powder. MS m/z 468 (M+H).

The requisite 1-N-BOC-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine was prepared as follows:

a) 1-N-BOC-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl) piperidine.

- 17 -

To a stirred solution containing 1-N-BOC-4-aminomethyl-4-(3,4-dichlorophenyl)piperidine (260.8 mg, 0.726 mmol), 3-cyano-2-methoxy-1-naphthoic acid (164.6 mg, 0.724 mmol), HOBt hydrate (290 mg, 1.89 mmol), N-methylmorpholine (0.17 mL), and DCM (15 mL) was added 1-(3-(dimethylamino)propyl-3-ethylcarbodiimide hydrochloride (215.5 mg, 1.12 mmol). After 72h, the mixture was diluted with 30% hexane/EtOAc, washed successively with water (2X), 0.1 N aq. HCl (2X), sat. aq. NaHCO<sub>3</sub>, dried, filtered, and concentrated. The residue was purified by chromatography (0-1% MeOH/DCM) to give the title compound as a white, foamy solid. MS m/z 468.

b) 1-N-BOC-4-aminomethyl-4-(3,4-dichlorophenyl)piperidine

10 A mixture containing 1-N-BOC-4-(3,4-dichlorophenyl)-4-cyanopiperidine (5.25 g, 14.78 mmol), Raney Ni catalyst (5g of 50% aq. slurry), EtOH (175 mL), and ammonium hydroxide (88 mL) was placed under a hydrogen atmosphere (50 psi) and agitated (Parr apparatus) for 18 h. The mixture was filtered through diatomaceous earth, concentrated, and purified by chromatography (0-5% MeOH/DCM) to give the title compound as an off-white solid. MS m/z 344 (M+1-CH<sub>3</sub>).  
15 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.44 (d, 1H), 7.38 (d, 1H), 7.15 (m, 1H), 3.7 (br d, 2H), 3.07 (m, 2H), 2.76 (s, 2H), 2.08 (br d, 2H), 1.71 (m, 2H), 1.44 (s, 9H).


c) 1-N-BOC-4-(3,4-dichlorophenyl)-4-cyanopiperidine

A solution containing bis(2-chloroethyl)-N-BOC amine (described in US Patent 5,661,163) (8.15 g, 33.67 mmol), 3,4-dichlorophenylacetonitrile (5.05 g, 27.17 mmol), and  
20 DMSO (50 mL) was stirred at RT and solid cesium carbonate (17.6 g, 54.02 mmol) was added (in portions) over 10 minutes. After 20 h, additional cesium carbonate (1.7 g.) was added, and the mixture stirred for an additional 72 h. The mixture was partitioned between water and EtOAc, the aq. layer was removed, and the organic layer washed successively with additional water, 0.1M aq. HCl (2X), sat. aq. NaHCO<sub>3</sub>, and brine. The organic layer was dried, filtered, concentrated,  
25 and the residue triturated (3:1 hexane/ethyl acetate) to give the title compound as an off-white solid, m.p. 142-145 °C. MS m/z 255 . <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.55 (d, 1H), 7.49 (d, 1H), 7.32 (m, 1H), 4.3 (br d, 2H), 3.18 (br t, 2H), 2.07 (d, 2H), 1.89 (m, 2H), 1.48 (s, 9H).

Example 4: 1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-  
30 2-azaprop-1-yl)piperidine.

The title compound of the following structure


- 18 -



was prepared as a citrate, as follows. A solution containing 4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl) piperidine (103 mg, 0.22 mmol), formic acid (0.25 mL), and 37% aq. formaldehyde (2 mL) was heated at 100 °C. for 18h, then cooled and concentrated. The residue was partitioned between DCM and sat. aq. NaHCO<sub>3</sub> and the organic layer was removed. The basic aq. layer was extracted with additional DCM (2X), and the combined organic extracts were dried, filtered, and concentrated. The residue was purified by chromatography (Chromatotron - silica rotor) (5% MeOH/DCM w/0.5% aq. NH<sub>3</sub>) and converted to the citrate salt to give the title compound as a white powder. MS m/z 482 (M+H).

Example 5: 4-(4-Chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure



was prepared as a citrate, as follows. In the same manner as Example 3, but using 1-N-BOC-4-(4-chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine (350 mg, 0.655 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound as a white powder. MS m/z 434 (M+H).

The requisite 1-N-BOC-4-(4-chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine was prepared as follows:

a) 1-N-BOC-4-(4-chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

- 19 -

In the same manner as Example 3a, but using 1-N-BOC-4-aminomethyl-4-(4-chlorophenyl) piperidine (244 mg, 0.75 mmol), 3-cyano-2-methoxy-1-naphthoic acid (170 mg, 0.748 mmol), HOBt hydrate (281 mg, 1.83 mmol), N-methylmorpholine (0.165 mL), 1-(3-(dimethylamino)propyl-3-ethylcarbodiimide hydrochloride (240 mg, 1.25 mmol), and DCM (10 mL), to yield the title compound as a foamy solid. MS m/z 434 .

b) 1-N-BOC-4-aminomethyl-4-(4-chlorophenyl) piperidine.


In the same manner as Example 3b, but using 1-N-BOC-4-(4-chlorophenyl)-4-cyanopiperidine (1.05 g, 3.26 mmol), Raney Ni catalyst (1.4 g of 50% aq. slurry), EtOH (50 mL), and ammonium hydroxide (25 mL), to yield the title compound as a viscous oil. MS m/z 310 (M+H-Me).

c) 1-N-BOC-4-(4-chlorophenyl)-4-cyanopiperidine.

A solution containing bis(2-chloroethyl)-N-BOC amine (3.72 g, 15.38 mmol), 4-chlorobenzyl cyanide (2.10 g, 13.88 mmol), and anhydrous DMF (15 mL) was stirred and NaH (60% dispersion in mineral oil) (1.6 g, 40 mmol) was added in portions over 1h. The mixture was heated at 60-65 °C. for 1h, stirred at RT for 72h, then was poured into ice/water and extracted with EtOAc (2X). The organic extracts were washed (water and brine), dried, filtered, and concentrated. The residue was purified by chromatography (8:1:1 hexane/DCM/EtOAc) to give the title compound as a yellow solid. MS m/z 221 .

20 Example 6: 1-N-Methyl-4-(4-chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate, as follows. In the same manner as Example 4, but using 4-(4-chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine (71.5 mg, 0.165 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound as a white powder. MS m/z 448 (M+H).

- 20 -

Example 7: 1-N-(2-Methoxyethyl)-4-(4-chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl) piperidine.


The title compound of the following structure



5 was prepared as a citrate, as follows. A solution containing 4-(4-chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl) piperidine (38.5 mg, 0.089 mmol), 2-bromoethyl methyl ether (55.5 mg, 0.40 mmol), TEA (0.075 mL), and DMF (0.5 mL) was heated (microwave) at 60 °C. for 1.25 h, stirred at RT overnight, diluted with EtOAc, then washed  
10 successively with water (2X) and sat. aq. NaHCO<sub>3</sub>. The organic phase was dried, filtered, and concentrated. The residue was purified by chromatography (2-5% MeOH/DCM w/ 0.5% aq. NH<sub>3</sub>), converted to the citrate salt, and isolated by filtration from Et<sub>2</sub>O to give the title compound as a white powder. MS m/z 492 (M+H).

15 Example 8: 4-(3,4-Dichlorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure



was prepared as a citrate, as follows. In the same manner as Example 3, but using 1-N-BOC-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine  
20 (801 mg, 1.34 mmol), TFA (25 mL), and DCM (25 mL), the citrate salt of to yield the title compound as a white, foamy solid. MS m/z 498 (M+H).

The requisite 1-N-BOC-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine was prepared as follows:


- 21 -

1-N-BOC-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

A solution containing 3-cyano-2,4-dimethoxy-1-naphthoyl chloride (described in international publication WO 00/20389) (408.3 mg, 1.48 mmol) and dry DCM (2.5 mL) was added in portions (0.25 mL) to a stirred, cooled (ice bath) solution containing 1-N-BOC-4-(3,4-dichlorophenyl)-4-aminomethylpiperidine (537 mg, 1.49 mmol), TEA (0.42 mL), and dry DCM (20 mL). After 1h, the reaction was warmed to RT, stirred an additional 1.5h, then concentrated. The residue was partitioned between water and EtOAc and the organic phase was removed and washed successively with 0.1N aq. HCl (2X), water, sat. aq. NaHCO<sub>3</sub> (2X), and brine. The organic phase was dried, filtered, concentrated, and the residue purified by chromatography (0-1% MeOH/DCM) to give the title compound as an off-white, foamy solid. MS m/z 498 .

Example 9: 4-(3,4-Dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure



was prepared as a citrate, as follows. In the same manner as Example 3, but using 1-N-BOC-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine (166.8 mg, 0.294 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound as a white powder. MS m/z 466 (M+H).

The requisite 1-N-BOC-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine was prepared as follows:

1-N-BOC-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.


In the same manner as Example 3a, but using 1-N-BOC-4-aminomethyl-4-(3,4-dichlorophenyl) piperidine (375 mg, 1.04 mmol), 3-cyano-2-ethyl-1-naphthoic acid (described in international publication WO 00/20389, (233 mg, 1.04 mmol), HOBt hydrate (399 mg, 2.6

- 22 -

mmol), N-methylmorpholine (0.23 mL), 1-(3-(dimethylamino)propyl-3-ethylcarbodiimide hydrochloride (330 mg, 1.72 mmol), and DCM (10 mL), to yield the title compound as a foamy solid. MS m/z 466 .

5 Example 10: 1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.


The title compound of the following structure



was prepared as a citrate, as follows. In the same manner as Example 4, but using 4-(3,4-  
 10 dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine (69 mg, 0.148 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound as a white powder. MS m/z 480 (M+H).

15 Example 11: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine.

The title compound of the following structure



was prepared as a citrate salt as follows. To a solution containing 3-cyano-1-naphthoic acid (0.435 g, 2.21 mmol), 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine (0.539 g, 2.43  
 20 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.676 g, 3.53 mmol) and 1-hydroxybenzotriazole (0.600 g, 4.44 mmol) in DCM (20 mL) was added TEA (0.92 mL, 6.60 mmol). The solution was stirred at room temperature overnight. The mixture was partitioned between DCM and sat. NaHCO<sub>3</sub>, the organic layer was removed, and the aq. layer extracted with



- 23 -

DCM (2x). The organic extracts were combined, dried, filtered, and concentrated. The residue was purified by chromatography (1-5% MeOH-DCM w/1% aq. NH<sub>3</sub>) to give the title compound as a white solid (0.7 g, 79% yield). MS m/z 402.50 (M+H). The citrate salt was obtained by standard procedure.

5        The requisite 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine was prepared as follows:

a) 1-N-Methyl-4-(4-fluorophenyl)-4-cyanopiperidine


To a solution containing mechlorethamine hydrochloride (1.923 g, 9.99 mmol) and 4-fluorophenyl acetonitrile (1.35 g, 9.99 mmol) in DMF (30 mL) was added sodium hydride (1.6 g, 10 40 mmol) slowly at 0 °C. The resulting suspension was stirred and heated at 60 °C for 24 hrs. The reaction mixture was quenched with ice water, extracted with EtOAc (3x). The organic extracts were combined, washed with sat. NaCl (3x), dried, filtered, and concentrated. The residue was purified by chromatography (2-5% MeOH-DCM) to give the title compound as a yellow oil (1.788 g, 82% yield). MS m/z 219.38 (M+H).

15    b) 1-N-Methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine

To a solution of 1-N-methyl-4-(4-fluorophenyl)-4-cyanopiperidine (1.788 g, 8.20 mmol) in dry THF (25 mL) was added LAH (1M in THF, 25mL, 24.6 mmol). The solution was stirred at room temperature overnight. The reaction was quenched by adding water (2.5 mL), followed by 15% NaOH (2.5 mL) and water (2.5 mL). The mixture was then filtered through diatomaceous 20 earth, washed with EtOAc, dried, filtered, and concentrated to give the title compound as a yellow oil (1.619 g, 89% yield). MS m/z 223.45 (M+H).

Example 12: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine.

25        The title compound of the following structure




- 24 -

was prepared as a citrate salt in the same manner as Example 11, but using 3-cyano-2-methoxy-1-naphthoic acid (100 mg, 0.44 mmol), 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine (107 mg, 0.48 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (135 mg, 0.704 mmol), 1-hydroxybenzotriazole (119 mg, 0.88 mmol), DCM (5 mL), and TEA (0.184 mL, 1.32 mmol), to yield the title compound as a white solid. 74% yield, MS m/z 432.46 (M+H).

Example 13: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine.

The title compound of the following structure



10


was prepared as a citrate salt as follows. To a solution containing 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine (98 mg, 0.441 mmol) and TEA (0.13 mL, 0.933 mmol) in DCM (5 mL) was added 3-cyano-2-ethyl-1-naphthoyl chloride (108 mg, 0.443 mmol) in DCM (1 mL) at 0 °C. The solution was stirred at 0 °C for 30 min and room temperature overnight. The mixture was partitioned between DCM and sat. NaHCO<sub>3</sub>, the organic layer was removed, and the aq. layer extracted with DCM (2x). The organic extracts were combined, dried, filtered, and concentrated. The residue was purified by chromatography (1-5% MeOH-DCM w/1% aq. NH<sub>3</sub>) to give the title compound as a light yellow solid (156 mg, 82% yield). MS m/z 430.51 (M+H). The citrate salt was obtained by standard procedure.

20

Example 14: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine.

The title compound of the following structure


- 25 -




was prepared as a citrate salt as follows. To a solution of 1-N-methyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine (366 mg, 0.912 mmol) in dry DMF (9 mL) was added NaH (44 mg, 1.1 mmol). The mixture was stirred at room temperature for 30 min and cooled to 0 °C. Methyl iodide (0.085 mL, 1.36 mmol) was added and the mixture was stirred at 0 °C for 30 min, room temperature overnight. The mixture was partitioned between EtOAc and water, the organic layer was removed, and the aq. layer extracted with EtOAc (2x). The organic extracts were combined, washed with sat. NaCl (3x), dried, filtered, and concentrated. The residue was purified by chromatography (1-5% MeOH-DCM w/1% aq. NH<sub>3</sub>) to give the title compound as a white solid (164 mg, 43% yield). MS m/z 416.54 (M+H). The citrate salt was obtained by standard procedure.

#### Examples 15 - 38:


The compounds of Examples 15 through 38 were prepared by processes similar to those given in Examples 11-14 but with replacement of 4-fluorophenyl acetonitrile with an appropriately substituted phenyl acetonitrile, compounds of Examples 15 through 38 and intermediates listed in Table 2 were obtained.



Example #



Intermediate (a)



Intermediate (b)

- 26 -

Table 2


Example #	Ar	R <sup>1a</sup>	R <sup>2</sup>	R <sup>1b</sup>	Yield (%)	MS m/z (M+H)
11	4-fluorophenyl	H	H	H	79	402.50
11 (a)	4-fluorophenyl				82	219.38
11 (b)	4-fluorophenyl				89	223.45
12	4-fluorophenyl	OMe	H	H	74	432.46
13	4-fluorophenyl	Et	H	H	82	430.51
14	4-fluorophenyl	H	Me	H	43	416.54
15	3,4-difluorophenyl	H	H	H	81	420.52
15 (a)	3,4-difluorophenyl				77	237.41
15 (b)	3,4-difluorophenyl				92	241.45
16	3,4-difluorophenyl	OMe	H	H	74	450.46
17	3,4-difluorophenyl	Et	H	H	44	448.51
18	3,4-difluorophenyl	H	Me	H	50	434.44
19	4-methoxyphenyl	H	H	H	78	414.53
19 (a)	4-methoxyphenyl				100	231.46
19 (b)	4-methoxyphenyl				93	235.49
20	4-methoxyphenyl	OMe	H	H	77	444.50
21	4-methoxyphenyl	Et	H	H	31	442.54
22	4-methoxyphenyl	H	Me	H	37	428.54
23	3,4-dimethoxyphenyl	H	H	H	67	444.52
23 (a)	3,4-dimethoxyphenyl				92	261.49
23 (b)	3,4-dimethoxyphenyl				86	265.52
24	3,4-dimethoxyphenyl	OMe	H	H	76	474.49
25	3,4-dimethoxyphenyl	Et	H	H	23	472.54
26	3,4-dimethoxyphenyl	H	Me	H	47	458.53
27	3,4-methylenedioxyphenyl	H	H	H	83	428.51
27 (a)	3,4-methylenedioxyphenyl				88	245.44
27 (b)	3,4-methylenedioxyphenyl				90	249.46

- 27 -

28	3,4-methylenedioxyphenyl	OMe	H	H	83	458.48
29	3,4-methylenedioxyphenyl	Et	H	H	62	456.40
30	3,4-methylenedioxyphenyl	H	Me	H	21	442.40
31	4-difluoromethoxyphenyl	H	H	H	74	450.53
31 (a)	4-difluoromethoxyphenyl				81	267.43
31 (b)	4-difluoromethoxyphenyl				62	271.48
32	4-difluoromethoxyphenyl	OMe	H	H	72	480.51
33	4-difluoromethoxyphenyl	Et	H	H	39	478.54
34	4-difluoromethoxyphenyl	H	Me	H	38	464.48
35	4-trifluoromethylphenyl	H	H	H	75	452
35 (a)	4-trifluoromethylphenyl				79	269
35 (b)	4-trifluoromethylphenyl				78	273.5
36	4-trifluoromethylphenyl	OMe	H	H	73	482
37	4-trifluoromethylphenyl	OMe	H	OMe	73	512
38	4-trifluoromethylphenyl	Et	H	H	73	480

Example 39: 4-(4-Fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure



- 5 was prepared as a citrate in the same manner as Example 3, but using 1-N-BOC-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine (158 mg, 0.324 mmol), to yield the title compound as a white powder. MS m/z 388 (M+H).

The requisite 1-N-BOC-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine was prepared as follows:

- 10 a) 1-N-BOC-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

- 28 -

In the same manner as Example 3a, but using 1-N-BOC-4-aminomethyl-4-(4-fluoro)piperidine (1.68 g, 5.45 mmol), 3-cyano-1-naphthoic acid (980 mg, 4.97 mmol), HOBT (1.34 g, 9.92 mmol), triethylamine (2.08 mL), 1-(3-(dimethylamino)propyl-3-ethylcarbodiimide hydrochloride (1.52 g, 7.93 mmol), and DCM (30 mL), to yield the title compound as a foamy solid. MS m/z 388 (M+H-BOC).

b) 1-N-BOC-4-aminomethyl-4-(4-fluorophenyl) piperidine.

In the same manner as Example 3b, but using 1-N-BOC-4-(4-fluorophenyl)-4-cyanopiperidine (4.64 g, 15.2 mmol), Raney Ni catalyst (1.4 g of 50% aq. slurry), EtOH (30 mL), and ammonium hydroxide (20 mL), to yield the title compound as a viscous oil. MS m/z 209 (M+H-BOC).

c) 1-N-BOC-4-(4-fluorophenyl)-4-cyanopiperidine.

To a solution of 4-(4-fluorophenyl)-4-cyanopiperidine (3.63 g, 17.8 mmol) in THF (90 mL) was added BOC-anhydride (3.88 g, 17.8 mmol) and DIPEA (3.10 mL, 17.8 mmol). The resulting solution was stirred at room temperature for overnight and poured into 0.1 N HCl. The aq. layer was extracted with EtOAc (2x80 mL). Combined EtOAc were dried over MgSO<sub>4</sub>, filtered and concentrated. The residue was purified by chromatography (1% MeOH/DCM) to give the title compound as a yellow oil. MS m/z 205 (M+H-BOC).


d) 4-(4-fluorophenyl)-4-cyanopiperidine

A solution containing bis(2-chloroethyl)amine hydrochloride (4.0 g, 22.4 mmol), 4-fluorobenzyl cyanide (3.03 g, 22.4 mmol), and anhydrous DMF (100 mL) was stirred at 0 °C and NaH (60% dispersion in mineral oil) (3.6 g, 90 mmol) was added in portions. The mixture was heated at 60 °C overnight, then was poured into ice/water and extracted with EtOAc (2X). The organic extracts were washed (water and brine), dried, filtered, and concentrated. The residue was purified by chromatography (1% MeOH/DCM) to give the title compound as a yellow oil. MS m/z 205 (M+H).

Example 40: 4-(4-Fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine.

The title compound of the following structure

- 29 -




was prepared as a citrate in the same manner as Example 3, but using 1-N-BOC-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine (1.5 g, 2.99 mmol), to yield the title compound as a white powder. MS m/z 402 (M+H).

- 5 The requisite 1-N-BOC-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine was prepared in the same manner as Example 14 but using 1-N-BOC-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine instead of 1-N-methyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

- 10 Example 41: 4-(4-Fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine.

The title compound of the following structure




- 15 was prepared as a citrate in the same manner as Example 3, but using 3-cyano-2-methoxy-1-naphthoic acid instead of 3-cyano-1-naphthoic acid in 3a, to yield the title compound as a white powder. MS m/z 418 (M+H).

- Example 42: 4-(4-Fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine.

- 20 The title compound of the following structure

- 30 -




was prepared as a citrate in the same manner as Example 3, to yield the title compound as a white powder. MS m/z 416 (M+H).

The requisite 1-N-BOC-4-(4-fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine was prepared in the same manner as Example 13, but using 1-N-BOC-4-amionmethyl-4-(4-fluoro)piperidine instead of 1-N-methyl-4-amionmethyl-4-(4-fluoro)piperidine.

Example 43: 4-(4-Fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine.

The title compound of the following structure




was prepared as a citrate in the same manner as Example 42, but using 3-cyano-2,4-dimethoxy-1-naphthoyl chloride instead of 3-cyano-2-ethyl-1-naphthoyl chloride, to yield the title compound as a white powder. MS m/z 448 (M+H).

Example 44: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine.

The title compound of the following structure



- 31 -




was prepared as a citrate in the same manner as Example 13, but using 3-cyano-2,4-dimethoxy-1-naphthoyl chloride instead of 3-cyano-2-ethyl-1-naphthoyl chloride, to yield the title compound as a white powder. MS  $m/z$  462 (M+H).

5

Example 45: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-fluoronaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine.

The title compound of the following structure




10 was prepared as a citrate in the same manner as Example 11, but using 4-fluoro-1-naphthoic acid instead of 3-cyano-1-naphthoic acid, to yield the title compound as a white powder. MS  $m/z$  395 (M+H).

Example 46: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-fluoronaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine.

15

The title compound of the following structure




was prepared as a citrate in the same manner as Example 14, but using 1-N-methyl-4-(4-fluorophenyl)-4-(3-(4-fluoronaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine instead of 1-N-

- 32 -

methyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine, to yield the title compound as a white powder. MS m/z 409 (M+H).

5 Example 47: 1-N-Methyl-4-(3,4-difluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine.


The title compound of the following structure



was prepared as a citrate in the same manner as Example 45, but using 1-N-methyl-4-(3,4-difluorophenyl)-4-(aminomethyl)piperidine instead of 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine, to yield the title compound as a light yellow powder. MS m/z 480 (M+H).

10 Example 46: 1-N-Ethyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

15 The title compound of the following structure



was prepared as a citrate in the same manner as Example 11, but using 1-N-ethyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine instead of 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine, to yield the title compound as a white powder. MS m/z 416 (M+H).

20 The requisite 1-N-ethyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine was prepared as follows:

a) 1-N-Ethyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine

- 33 -


To a solution of 1-N-(1-oxoethyl)-4-(4-fluorophenyl)-4-cyanopiperidine (3.4 g, 13.8 mmol) in THF (50 mL) was added LAH (1 N in THF, 55 mL, 55.2 mmol). The solution was heated to 70 °C for 3 hours. The reaction was quenched by adding water (5.5 mL), 15% NaOH (5.5 mL) and water (5.5 mL). The mixture was filtered through diatomaceous earth, washed with EtOAc. The organic layer was dried, filtered and concentrated. The residue was purified by chromatography (5%, 10% MeOH/DCM, 20% MeOH/DCM with 2% NH<sub>4</sub>OH) to give the title compound as a yellow oil. MS m/z 237 (M+H).

b) 1-N-(1-Oxoethyl)-4-(4-fluorophenyl)-4-cyanopiperidine

To a solution of 4-(4-fluorophenyl)-4-cyanopiperidine (3.33 g, 16.3 mmol) and triethylamine (4.77 mL, 34.2 mmol) in DCM (90 mL) was added acetyl chloride (1.16 mL, 16.3 mmol) at 0 °C. The solution was stirred at 0 °C for 0.5 hour and room temperature for 17 h. NaHCO<sub>3</sub> (sat.) was added. The mixture was extracted with DCM (2x), dried, filtered and concentrated. The residue was purified by chromatography (30%, 50%, 60%, 80% and 90% EtOAc/hexane) to give the title compound as a yellow oil. MS m/z 247 (M+H).

Example 49: 1-N-Ethyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate in the same manner as Example 12, but using 1-N-ethyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine instead of 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine, to yield the title compound as a white powder. MS m/z 446 (M+H).

Example 50: 1-N-Ethyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-N-methyl-2-azaprop-1-yl)piperidine.

The title compound of the following structure


- 34 -



was prepared as a citrate in the same manner as Example 14, but using 1-N-ethyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine instead of 1-N-methyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine, to yield  
 5 the title compound as a white powder. MS m/z 430 (M+H).

Example 51: 1-N-Ethyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-ethyl-naphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure



10


was prepared as a citrate in the same manner as Example 13, but using 1-N-ethyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine instead of 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine, to yield the title compound as a light yellow powder. MS m/z 444 (M+H).

15

Example 52: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine.

The title compound of the following structure

- 35 -




was prepared as a citrate in the same manner as Example 45, but using 1-N-ethyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine instead of 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine, to yield the title compound as a white powder. MS m/z 476 (M+H).

5

Example 53: 1-N-Ethyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure



10 was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-ethyl-4-aminomethyl-4-(3,4-dichlorophenyl)piperidine (76 mg, 0.265 mmol) and 3-cyano-2-methoxy-1-naphthoyl chloride (71 mg, 0.29 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (116 mg) (63%) as a white powder. MS m/z 496 (M+H).

The requisite 1-N-ethyl-4-aminomethyl-4-(3,4-dichlorophenyl)piperidine was prepared as follows:

a) 1-N-ethyl-4-aminomethyl-4-(3,4-dichlorophenyl)piperidine

To a stirred solution containing 1-N-(1-oxoethyl)-4-(3,4-dichlorophenyl)-4-cyanopiperidine (623 mg, 2.097 mmol) and dry THF (10 mL), a solution of BH<sub>3</sub> in THF (20 mL of 1M) was slowly added. The solution was heated under reflux for 21 h, cooled to ambient, and cautiously treated with 1 N aq. HCl (10 mL). After 0.5 h, the volume was reduced by evaporation, sat. aq. NaHCO<sub>3</sub> was added (until basic), and the mixture was extracted with DCM (4X). The extracts were dried (MgSO<sub>4</sub>), filtered, and concentrated. The residue was treated with 8 N aq. HCl (25 mL), stirred with intermittent heating for 72 h., basified (33% aq. NaOH), and

- 36 -

extracted with DCM (4X). The DCM extracts were washed (brine), dried ( $\text{MgSO}_4$ ), filtered, and concentrated. The residue was purified by chromatography (0-5% MeOH/DCM w/ 1%  $\text{NH}_3$ ) to give the title compound (315 mg) (52%) as an off-white solid. MS m/z 287 (M+H).

b) 1-N-(1-oxoethyl)-4-(3,4-dichlorophenyl)-4-cyanopiperidine

5 A stirred solution containing 4-(3,4-dichlorophenyl)-4-cyanopiperidine (535 mg, 2.097 mmol), TEA (0.44 mL), and dry DCM (15 mL) was cooled (ice bath) and acetyl chloride (210 mg, 2.67 mmol) was added dropwise. After 1h, the mixture was warmed to RT, stirred for an additional 18 h, diluted with DCM, and washed with sat. aq.  $\text{NaHCO}_3$ . The organic phase was dried ( $\text{MgSO}_4$ ), filtered, and concentrated. The residue was purified by chromatography (0-2%  
10 MeOH/DCM) to give the title compound (quantitative) as an off-white, solid. MS m/z 297 (M+H).


c) 4-(3,4-dichlorophenyl)-4-cyanopiperidine

A solution containing 1-N-BOC-4-(3,4-dichlorophenyl)-4-cyanopiperidine (Example 3c) (5.54 g, 15.59 mmol), TFA (50 mL), and DCM (50 mL) was stirred at RT for 18 h, then  
15 concentrated. The residue was treated with water, sodium bicarbonate, and sat. aq. sodium bicarbonate (until basic), then extracted with DCM (3X). The DCM extracts were dried ( $\text{Na}_2\text{SO}_4$ ), filtered, and concentrated. The residue was purified by chromatography (0-5% MeOH/DCM) to give the title compound (3.81g) (95%) as an off-white solid. MS m/z 255 (M+H).

20

Example 54: 1-N-Ethyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




25 was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-ethyl-4-aminomethyl-4-(3,4-dichlorophenyl)piperidine (151 mg, 0.525 mmol) and 3-cyano-1-

- 37 -

naphthoyl chloride (124 mg, 0.577 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound 115 mg (76%) as a white powder. MS m/z 466 (M+H).

Example 55: 1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.


The title compound of the following structure



was prepared as a citrate salt, as follows. In the same manner as Example 11, but using 1-N-methyl-4-aminomethyl-4-(3,4-dichlorophenyl)piperidine (237 mg, 0.867 mmol) and 3-cyano-1-naphthoic acid (168 mg, 0.852 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (306 mg) (57%) as a white powder. MS m/z 452 (M+H).

Example 56: 1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure



was prepared as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(3-fluorophenyl)piperidine (172 mg, 0.775 mmol) and 3-cyano-1-naphthoyl chloride (164.5 mg, 0.763 mmol), the title compound (139 mg) (45%) was obtained as a white powder. MS m/z 402 (M+H).

The requisite 1-N-methyl-4-aminomethyl-4-(3-fluorophenyl)piperidine was prepared as follows:

a) 1-N-methyl-4-cyano-4-(3-fluorophenyl)piperidine

- 38 -


In the same manner as Example 11a, but using 3-fluorophenylacetonitrile (5.05 g, 37.4 mmol), and following short-path distillation, the title compound (7.96 g) (97%) was obtained as a colorless liquid. MS  $m/z$  219 (M+H).

b) 1-N-methyl-4-aminomethyl-4-(3-fluorophenyl)piperidine

5 In the same manner as Example 11b, but using 1-N-methyl-4-cyano-4-(3-fluorophenyl)piperidine (3.08 g, 14.1 mmol), and following short-path distillation, the title compound (2.95 g) (94%) was obtained as a colorless liquid. MS  $m/z$  223 (M+H).

10 Example 57: 1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.


The title compound of the following structure



15 was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(3-fluorophenyl)piperidine (166.2 mg, 0.748 mmol) and 3-cyano-2-methoxy-1-naphthoyl chloride (178.8 mg, 0.728 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (325 mg) (72%) as a white powder. MS  $m/z$  432 (M+H).

20 Example 58: 1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure



was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(3-fluorophenyl)piperidine (151.9 mg, 0.683 mmol) and 3-cyano-2-




- 39 -

ethyl-1-naphthoyl chloride (163.2 mg, 0.67 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (272 mg) (65%) as a white powder. MS m/z 430 (M+H).

5 Example 59: 1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.


The title compound of the following structure



was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(3-fluorophenyl)piperidine (154.8 mg, 0.696 mmol) and 3-cyano-2,4-dimethoxy-1-naphthoyl chloride (187.3 mg, 0.679 mmol), the citrate salt was isolated by  
10 filtration from Et<sub>2</sub>O to give the title compound (247 mg) (55%) as a white powder. MS m/z 462 (M+H).

15 Example 60: 1-N-Methyl-4-phenyl-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure



was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-phenylpiperidine (159 mg, 0.776 mmol) and 3-cyano-1-naphthoyl chloride (164.5 mg, 0.763 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the  
20 title compound (278 mg) (65%) as a white powder. MS m/z 384 (M+H).

The requisite 1-N-methyl-4-aminomethyl-4-phenylpiperidine was prepared as follows:

a) 1-N-methyl-4-cyano-4-phenylpiperidine

- 40 -


In the same manner as Example 11a, but using phenylacetonitrile (4.4 g, 37.6 mmol), and following short-path distillation, the title compound (7.05 g) (93%) was isolated as a colorless liquid. MS m/z 201 (M+H).

b) 1-N-methyl-4-aminomethyl-4-phenylpiperidine

5 In the same manner as Example 1c, but using 1-N-methyl-4-cyano-4-phenylpiperidine (3.09 g, 15.4 mmol), and following short-path distillation, the title compound (2.71 g) (94%) was isolated as a colorless liquid. MS m/z 205 (M+H).

10 Example 61: 1-N-Methyl-4-phenyl-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.


The title compound of the following structure



was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-phenylpiperidine (151 mg, 0.738 mmol) and 3-cyano-2-methoxy-1-naphthoyl chloride (175 mg, 0.713 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (381 mg) (90%) as a white powder. MS m/z 414 (M+H).

20 Example 62: 1-N-Methyl-4-phenyl-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-phenylpiperidine (140.4 mg, 0.687 mmol) and 3-cyano-2-ethyl-1-

- 41 -

naphthoyl chloride (163.2 mg, 0.67 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (257 mg) (64%) as a white powder. MS m/z 412 (M+H).

Example 63: 1-N-Methyl-4-phenyl-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.


The title compound of the following structure



was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-phenylpiperidine (147.5 mg, 0.722 mmol) and 3-cyano-2,4-dimethoxy-1-naphthoyl chloride (187.3 mg, 0.679 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (171 mg) (39%) as a white powder. MS m/z 444 (M+H).

Example 64: 1-N-Methyl-4-phenyl-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine.

The title compound of the following structure




was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-(N-methylaminomethyl)-4-phenylpiperidine (109 mg, 0.497 mmol) and 3-cyano-1-naphthoyl chloride (107 mg, 0.497 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (141 mg) (48%) as a white powder. MS m/z 398 (M+H).

Example 65: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-methoxy-4-methylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure


- 42 -



was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(4-fluorophenyl)piperidine (107.5 mg, 0.484 mmol) and 3-methoxy-4-methyl-1-naphthoyl chloride (108.5 mg, 0.462 mmol), the citrate salt was isolated by filtration  
 5 from Et<sub>2</sub>O to give the title compound (217 mg) (78%) as a white powder. MS m/z 421 (M+H).

Example 66: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-chloro-3-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




10

was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(4-fluorophenyl)piperidine (107 mg, 0.48 mmol) and 4-chloro-3-methoxy-1-naphthoyl chloride (115.5 mg, 0.453 mmol), the citrate salt was isolated by filtration  
 15 from Et<sub>2</sub>O to give the title compound (187 mg) (67%) as a white powder. MS m/z 441 (M+H).

15

Example 67: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-4-methylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




- 43 -

was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(4-fluorophenyl)piperidine (122 mg, 0.549 mmol) and 3-cyano-4-methyl-1-naphthoyl chloride (110.9 mg, 0.483 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (224 mg) (76%) as a white powder. MS m/z 416 (M+H).

5

Example 68: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-4-methylnaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine.

The title compound of the following structure




10 was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-(methylaminomethyl)-4-(4-fluorophenyl)piperidine (132 mg, 0.558 mmol) and 3-cyano-4-methyl-1-naphthoyl chloride (108 mg, 0.47 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (250 mg) (88%) as a white powder. MS m/z 430 (M+H).

15

Example 69: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-bromonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




20 was prepared as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(4-fluorophenyl)piperidine (174.6 mg, 0.785 mmol) and 4-bromo-1-naphthoyl chloride (177 mg, 0.656 mmol), the title compound (214 mg) (71%) was obtained as a white powder. MS m/z 455 (M+H).

- 44 -

Example 70: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-bromonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine.


The title compound of the following structure




was prepared as follows. In the same manner as Example 13, but using 1-N-methyl-4-(methylaminomethyl)-4-(4-fluorophenyl)piperidine (188 mg, 0.796 mmol) and 4-bromo-1-naphthoyl chloride (179 mg, 0.664 mmol), the title compound (270.8 mg) (86%) was obtained as a white powder. MS m/z 469 (M+H).

#### Examples 71 - 79:


The compounds of Examples 71 through 79 were prepared by processes similar to those given in Examples 11-14 but with replacement of 4-fluorophenyl acetonitrile with an appropriately substituted phenyl acetonitrile, compounds of Examples 71 through 79 and intermediates listed in Table 3 were obtained.



Example #



Intermediate (a)



Intermediate (b)

**Table 3**

Example #	Ar	R <sup>1a</sup>	R <sup>2</sup>	R <sup>1b</sup>	Yield (%)	MS m/z (M+H)
71	3-fluorophenyl	H	H	H	45	402
71(a)	3-fluorophenyl				97	219
71(b)	3-fluorophenyl				94	223

- 45 -

72	3-fluorophenyl	MeO	H	H	72	432
73	3-fluorophenyl	Et	H	H	65	430
74	3-fluorophenyl	MeO	H	MeO	55	462
75	Phenyl	H	H	H	65	384
75(a)	Phenyl				93	201
75(b)	Phenyl				94	205
76	Phenyl	MeO	H	H	90	414
77	Phenyl	Et	H	H	64	412
78	Phenyl	MeO	H	MeO	39	444
79	Phenyl	H	Me	H	48	398

Example 80:

Following conventional procedures well known in the pharmaceutical art, the following representative pharmaceutical dosage forms containing a compound in accord with structural

5 diagram I may be prepared:

	TABLET	mg/tablet
	Compound in accord with structural diagram I	50.0
	Mannitol, USP	223.75
10	Croscarmellose sodium	60
	Maize starch	15
	Hydroxypropylmethylcellulose (HPMC), USP	2.25
	Magnesium stearate	3.0
15	CAPSULE	mg/capsule
	Compound in accord with structural diagram I	10.0
	Mannitol, USP	488.5
	Croscarmellose sodium	15
	Magnesium stearate	1.5

- 46 -


The pharmaceutical dosage form is administered to a patient in need thereof at a frequency depending on the patient and the precise disease condition being treated.



- 47 -

## CLAIMS

1. A compound in accord with structural diagram I:



I

wherein:

$R^1$  at each occurrence is independently selected from CN,  $CF_3$ ,  $OCF_3$ ,  $OCHF_2$ , halogen,  $C_{2-4}$ alkenyl,  $C_{2-4}$ alkynyl,  $R^a$ ,  $R^b$ ,  $SR^a$ ,  $NR^aR^b$ ,  $CH_2NR^aR^b$ ,  $OR^a$  or  $CH_2OR^a$ , where  $R^a$  and  $R^b$  are independently at each occurrence hydrogen,  $C_{1-6}$ alkyl,  $C(O)R^c$ ,  $C(O)NHR^c$  or  $CO_2R^c$ , where  $R^c$  at each occurrence is  $C_{1-6}$ alkyl; or,  $R^a$  and  $R^b$  together are  $(CH_2)_jG(CH_2)_k$  or  $G(CH_2)_jG$ , where G is oxygen or sulfur, j is 1, 2, 3 or 4, and k is 0, 1 or 2;

m is 1, 2 or 3 where at least one  $R^1$  moiety is other than hydrogen;

$R^2$  and  $R^3$  are independently hydrogen,  $C_{1-6}$ alkyl or  $C_{1-6}$ alkyl substituted with  $C_{1-4}$ alkoxy;

$R^4$  at each occurrence is independently selected from hydrogen, CN,  $CF_3$ ,  $OCF_3$ ,  $OCHF_2$ , halogen,  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{2-4}$ alkynyl,  $SR^a$ ,  $NR^aR^b$ ,  $CH_2NR^aR^b$ ,  $OR^a$  or  $CH_2OR^a$ , where  $R^a$  and  $R^b$  are independently at each occurrence hydrogen,  $C_{1-6}$ alkyl,  $C(O)R^c$ ,  $C(O)NHR^c$  or  $CO_2R^c$  where  $R^c$  at each occurrence is  $C_{1-6}$ alkyl; or,  $R^a$  and  $R^b$  together are  $(CH_2)_jG(CH_2)_k$  or  $G(CH_2)_jG$ , and

n is 0, 1, 2 or 3;

in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

2. A compound according to Claim 1, wherein:

$R^1$  independently at each occurrence is CN,  $C_{1-6}$ alkyl or  $OR^c$  and m is 1, 2 or 3;

$R^2$  and  $R^3$  are independently hydrogen or  $C_{1-6}$ alkyl, and


$R^4$  independently at each occurrence is halogen where n is 1 or 2;

in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

- 48 -

3. A compound according to Claim 1 wherein:  
 $R^1$  independently at each occurrence is CN, ethyl or methoxy and m is 1, 2 or 3;  
 $R^2$  and  $R^3$  are independently hydrogen or methyl, and  
 $R^4$  independently at each occurrence is halogen where n is 1 or 2;  
 5 in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

4. A compound according to Claim 1, according to structural diagram II



II

- 10 wherein Ar is selected from phenyl, 3,4-dichlorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 4-difluoromethoxyphenyl or 4-trifluoromethoxyphenyl;  
 $R^1$  is selected from H, methyl, ethyl or methoxy where m is 1 or 2, and  
 $R^2$  and  $R^3$  are independently selected from H or methyl, and  
 15 in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.
5. A pharmaceutically-acceptable salts of a compound according to Claim 1 made with an inorganic or organic acid which affords a physiologically-acceptable anion.
- 20 6. A pharmaceutically-acceptable salts of a compound according to Claim 5, wherein said inorganic or organic acid is selected from hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, sulfamic, para-toluenesulfonic, acetic, citric, lactic, tartaric, malonic, fumaric, ethanesulfonic, benzenesulfonic, cyclohexylsulfamic, salicylic and quinic acids.
- 25 7. A pharmaceutical composition comprising a compound according to Claim 1, an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable carrier.

- 49 -

8. A method of treating a disease condition wherein antagonism of NK<sub>1</sub> receptors in combination with SRI activity is beneficial which method comprises administering to a warm-blooded animal an effective amount of a compound according to Claim 1 or an in vivo-  
5 hydrolysable precursor or a pharmaceutically-acceptable salt thereof.

9. The use of a compound according to Claim 1 or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof in the preparation of a medicament for use in a disease condition wherein antagonism of the NK<sub>1</sub> receptors and SRI activity is beneficial.

10

10. A method for treating a disorder or condition selected from hypertension, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced  
15 depression, post partum depression, generalized anxiety disorder, agoraphobia, social phobia, simple phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, anorexia nervosa, bulimia nervosa, obesity, addictions to alcohol, cocaine, heroin, phenobarbital, nicotine or benzodiazepines; cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, dementia, amnestic disorders, age-related  
20 cognitive decline, dementia in Parkinson's disease, neuroleptic-induced parkinsonism, tardive dyskinesias, hyperprolactinaemia, vasospasm, cerebral vasculature vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder, chronic paroxysmal hemicrania and  
25 headache associated with vascular disorders in a mammal, comprising administering an effective amount of a compound according to Claim 1 or a pharmaceutically-acceptable salt thereof effective in treating such disorder or condition and a pharmaceutically-acceptable carrier.

11. The use of a compound according to Claim 1, for the preparation of a medicament useful  
30 for the treatment of hypertension, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression,

- 50 -

depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, post partum depression, generalized anxiety disorder, agoraphobia, social phobia, simple phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, anorexia nervosa, bulimia nervosa, obesity, 5 addictions to alcohol, cocaine, heroin, phenobarbital, nicotine or benzodiazepines; cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, dementia, amnestic disorders, age-related cognitive decline, dementia in Parkinson's disease, neuroleptic-induced parkinsonism, tardive dyskinesias, hyperprolactinaemia, vasospasm, cerebral vasculature vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of 10 schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder, chronic paroxysmal hemicrania and headache associated with vascular disorders in a mammal.

15

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/01329

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 211/26, A61K 31/451, A61P 25/00, A61P 9/00  
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, CHEM. ABS DATA, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9413639 A1 (MERCK SHARP & DOHME LIMITED), 23 June 1994 (23.06.94), claim 1, claim 10, line 16 - line 17, line 31 - line 33, page 16, line 31 - page 18, line 12 --	1-11
X	WO 0025786 A1 (MERCK & CO., INC.), 11 May 2000 (11.05.00), claims 2-9, page 52, line 5 - line 17 --	1-11
X	WO 0002859 A1 (ZENECA LIMITED), 20 January 2000 (20.01.00), the claims --	1-11
X	WO 02051807 A1 (ASTRAZENECA AB), 4 July 2002 (04.07.02), the claims, page 16, line 19 - line 20 --	1-11

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

29 October 2003

Date of mailing of the international search report

30-10-2003

Name and mailing address of the ISA/

Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Gerd Strande11/Eö  
Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/01329

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 0020389 A1 (ZENECA LIMITED), 13 April 2000 (13.04.00), the claims  --	1-11
A	Bioorganic & Medicinal Chemistry Letters, Volume 12, no. 2, January 2002, Thomas Ryckmans et al: "First Dual NK1 Antagonists-Serotonin Reuptake Inhibitors: Synthesis and SAR of a New Class of Poatential Antidepressants", page 261 - page 264  -- -----	1-11

# INTERNATIONAL SEARCH REPORT

International application No.  
**PCT/SE03/01329**

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **8, 10**  
because they relate to subject matter not required to be searched by this Authority, namely:  
**see next sheet\***
2. ☒ Claims Nos.: **1-4, 7-9 all in part**  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
**see next sheet\*\***
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE03/01329

\*

Claims 8 and 10 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practised on the human or animal body (Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds or compositions. These alleged effects must be well defined diseases or conditions.

\*\*

The expression "a disease condition wherein antagonism of NK<sub>1</sub> receptors in combination with SRI activity is beneficial" in claims 8 and 9 may relate to a number of different disorders and conditions, which can not be clearly (Article 6 PCT) defined by this expression. Thus, the search has mainly been restricted to the diseases mentioned in claims 10 and 11.

The scope of the claims 1-4 and 7-9, in as far as the expression "in vivo-hydrolysable precursor(s) thereof" is concerned, is so unclear (Article 6 PCT) that a meaningful International Search is impossible with regard to this expression.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established will not be the subject of an international preliminary examination (Rule 66.1(e) PCT). This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



**INTERNATIONAL SEARCH REPORT**

Information on patent family members

06/09/03

International application No.

PCT/SE 03/01329

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9413639	A1	23/06/94	AU	682838 B	23/10/97
				AU	5657394 A	04/07/94
				CA	2150951 A	23/06/94
				EP	0673367 A	27/09/95
				GB	9226014 D	00/00/00
				JP	8504435 T	14/05/96
				US	5661162 A	26/08/97
				GB	9313726 D	00/00/00
				GB	9314486 D	00/00/00
WO	0025786	A1	11/05/00	AU	764515 B	21/08/03
				AU	1133800 A	22/05/00
				CA	2348735 A	11/05/00
				EP	1126849 A	29/08/01
				JP	2002528503 T	03/09/02
				US	6146109 A	14/11/00
				US	6303637 B	16/10/01

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

06/09/03

PCT/SE 03/01329

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	0002859	A1	20/01/00	AU	4637899 A	01/02/00
				BR	9912013 A	10/04/01
				CA	2336806 A	20/01/00
				CN	1309638 T	22/08/01
				EP	1097137 A	09/05/01
				GB	9814886 D	00/00/00
				GB	9914886 D	00/00/00
				IL	140770 D	00/00/00
				JP	2002520316 T	09/07/02
				NO	20010151 A	05/03/01
				US	6365602 B	02/04/02
				AU	6111199 A	26/04/00
				BR	9915904 A	21/08/01
				CA	2345133 A	13/04/00
				CN	1322196 T	14/11/01
				EP	1119551 A	01/08/01
				GB	9821699 D	00/00/00
				GB	9922521 D	00/00/00
				IL	142045 D	00/00/00
				JP	2002526527 T	20/08/02
				NO	20011765 A	07/06/01
				NZ	510582 A	29/08/03
				WO	0020389 A	13/04/00
				ZA	200102651 A	01/07/02
				AT	230598 T	15/01/03
				AU	6111099 A	26/04/00
				BR	9914333 A	26/06/01
				CA	2344807 A	13/04/00
				CN	1322134 T	14/11/01
				DE	69904847 D	00/00/00
				EP	1119355 A,B	01/08/01
				SE	1119355 T3	
				GB	9821703 D	00/00/00
				GB	9922519 D	00/00/00
				IL	142048 D	00/00/00
				JP	2002526410 T	20/08/02
				NO	20011766 A	05/06/01
				US	6500818 B	31/12/02
				WO	0020003 A	13/04/00
				ZA	200102658 A	01/07/02
				GB	9909840 D	00/00/00
WO	02051807	A1	04/07/02	EP	1345899 A	24/09/03
				SE	0004827 D	00/00/00

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

06/09/03

PCT/SE 03/01329

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0020389 A1	13/04/00	AU 4637899 A	01/02/00
		AU 6111199 A	26/04/00
		BR 9912013 A	10/04/01
		BR 9915904 A	21/08/01
		CA 2336806 A	20/01/00
		CA 2345133 A	13/04/00
		CN 1309638 T	22/08/01
		CN 1322196 T	14/11/01
		EP 1097137 A	09/05/01
		EP 1119551 A	01/08/01
		GB 9821699 D	00/00/00
		GB 9914886 D	00/00/00
		GB 9922521 D	00/00/00
		IL 140770 D	00/00/00
		IL 142045 D	00/00/00
		JP 2002520316 T	09/07/02
		JP 2002526527 T	20/08/02
		NO 20010151 A	05/03/01
		NO 20011765 A	07/06/01
		NZ 510582 A	29/08/03
		US 6365602 B	02/04/02
		WO 0002859 A	20/01/00
		ZA 200102651 A	01/07/02
		GB 9906278 D	00/00/00
		GB 9909839 D	00/00/00

---